The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study (NASH‐CO study)

Abstract

AbstractBackgroundThe impact of non‐alcoholic fatty liver disease (NAFLD) on morbidity and mortality has yet to be documented at the general population level. This study aimed to assess whether NAFLD was associated with morbidities and mortality and to estimate its impact on health status and mortality.MethodsThe study population consisted of 137 206 participants from Constances cohort. Non‐invasive diagnosis of NAFLD and advanced fibrosis was performed using the fatty liver index and Forns index, respectively. Constances data were linked to health care and hospitalization data to identify liver‐related events, cardiovascular diseases (CVD), extrahepatic cancers (EHC), chronic kidney disease (CKD) and all‐cause mortality.ResultsThe prevalence of NAFLD was 18.3% in subjects without other chronic liver diseases, among whom 2.7% had fibrosis. NAFLD after IPTW‐weighted remained associated with an increased risk of death (HR 1.26, 95% CI 1.01–1.57), hepatic‐related complications (HR 2.48, 95% CI 1.99–3.29), CVD (HR 1.42, 95% CI 1.30–1.55), EHC (HR 1.11, 95% CI 1.01–1.28) and CKD (HR 1.81, 95% CI 1.53–2.07) compared to those without chronic liver diseases risk factors (Non‐NAFLD). In the trend analysis over the study period of inclusion and compared to Non‐NAFLD, NAFLD has shown a fastest growing cause of hepatic events (HR 1.38, 95% CI 1.07–1.76 per year), CVD (HR 1.08, 95% CI 1.03–1.12), CKD (HR 1.16, 95% CI 1.07–1.25), and death (HR 1.39, 95% CI 1.39–1.50).ConclusionThis large community‐based cohort showed that NAFLD was associated with excess morbidity and mortality and demonstrated a fastest‐growing trend.